Selected article for: "antiviral agent and dose infection"
Author: Kumaki, Yohichi; Ennis, Jane; Rahbar, Ramtin; Turner, Jeffrey D.; Wandersee, Miles K.; Smith, Aaron J.; Bailey, Kevin W.; Vest, Zachary G.; Madsen, Jason R.; Li, Joseph K.-K.; Barnard, Dale L.
Title: Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
  • Cord-id: q9tstj31
  • Document date: 2011_1_1
    • ID: q9tstj31
    Snippet: Interferons (IFNs) are a first line of defense against viral infection. Herein we describe the use of an adenovirus vectored mouse IFN alpha gene (mDEF201) as a prophylactic and treatment countermeasure in a SARS-CoV-infected BALB/c mouse model. Complete survival protection was observed in mice given a single dose of mDEF201 administered intranasally 1, 3, 5, 7, or 14 days prior to lethal SARS-CoV challenge (p<0.001), and body weights of these treated mice were unaffected by the challenge. In ad
    Document: Interferons (IFNs) are a first line of defense against viral infection. Herein we describe the use of an adenovirus vectored mouse IFN alpha gene (mDEF201) as a prophylactic and treatment countermeasure in a SARS-CoV-infected BALB/c mouse model. Complete survival protection was observed in mice given a single dose of mDEF201 administered intranasally 1, 3, 5, 7, or 14 days prior to lethal SARS-CoV challenge (p<0.001), and body weights of these treated mice were unaffected by the challenge. In addition, low doses of mDEF201 protected lungs in a dose dependent manner as measured by a reduction in gross pathology. Intranasal treatment with mDEF201 ranging from 10(6) to 10(8) PFU significantly protected mice against a lethal SARS-CoV infection in a dose dependent manner up to 12 h post infection (P<0.001). The data suggest that mDEF201 is a new class of antiviral agent further development as treatment for SARS-CoV infections.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and administration time dose: 1, 2, 3, 4
    • acute respiratory syndrome and live number: 1, 2
    • acute respiratory syndrome and logrank test: 1
    • acute respiratory syndrome and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung sample: 1, 2, 3, 4
    • administration time and live number: 1
    • administration time and lung pathology: 1
    • live number and lung pathology: 1
    • lost body weight and lung pathology: 1